Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

1.940 -0.100 (-4.90%)
Streaming Delayed Price Updated: 11:08 AM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,240
Open 2.060
Bid (Size) 1.940 (1)
Ask (Size) 2.050 (2)
Prev. Close 2.040
Today's Range 1.920 - 2.070
52wk Range 1.710 - 7.260
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia
Via Investor Brand Network
Silo Pharma To Patent Novel Ketamine-Based Treatment For Chronic Condition
Biopharma company Silo Pharma Inc. 
Via Benzinga

Performance

YTD
-36.81%
-36.81%
1 Month
-13.39%
-13.39%
3 Month
-43.27%
-43.27%
6 Month
-62.51%
-62.51%
1 Year
-61.96%
-61.96%

More News

Read More
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
From Silo Pharma, Inc.
Via Globe NewsWire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Psychedelic Trials Update: Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Positive Results from IND-Enabling Toxicology Study of SP-26
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Positive Results from IND-Enabling Study of SP-26 for Fibromyalgia
From Silo Pharma, Inc.
Via Globe NewsWire
Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression
Via Investor Brand Network
Exposures COVID-19
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands Intellectual Property, Technology Rights for Treating Rare Stress-Related Medical Conditions
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Alzheimer’s
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer’s
From Silo Pharma, Inc.
Via Globe NewsWire
BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Partnering to Transform Health Care, Improve Patient Outcomes
Via Investor Brand Network
Silo Pharma, Mindset Pharma, Terran Biosciences Receive Psychedelic Treatments Patents, IP Portfolios Expanded
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Expands IP Portfolio with New USPTO Patent
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Silo Pharma Announces Expansion of Intellectual Property Portfolio
From Silo Pharma, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.